TGF-β1, TNF-α and cytochrome c in human astrocytic tumors: A short-term follow up and correlation with survival

Clinical Biochemistry

Volumn 40, Issue 3-4, 2007, Pages 255-260

  Mabrouk, Gamal M ^a   Ali, Ehab M M ^b   El Rehany, Mahmoud A ^c   El Samoly, Hatem M ^d  

^a Faculty of Veterinary Medicine   (Egypt)

^b Tanta University   (Egypt)

^c MINIA UNIVERSITY   (Egypt)

^d AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Cytochrome c; Gliomas; Survival; TGF 1; TNF

Indexed keywords

CYTOCHROME C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER STAGING; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; CYTOPLASM; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEASUREMENT; PATIENT SATISFACTION; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; BRAIN TUMOR; CHILD; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYTOCHROMES C; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846239007     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.09.009     Document Type: Article

References (42)

1. Ganju V., Jenkins R.B., O'Fallon J.R., Scheithauer B.W., Ransom D.T., Katzmann J.A., et al. Prognostic factors in gliomas: a multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 74 (1994) 920-927
2. Gottfried Y., Voldavsky E., Yodoko L., Sabo E., Ben-Itzhak O., and Larisch S. Expression of the pro-apoptotic protein ARTS in astrocytic tumours: correlation with malignancy grade and survival rate. Cancer 101 (2004) 2614-2621
3. Ohgaki H., and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64 (2005) 479-489
4. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 25 (2005) 1-7
5. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., et al. The WHO classification of tumours of the nervous system. J. Neuropathol. Exp. Neurol. 61 (2002) 215-225
6. Kuriyama H., Lamborn K.R., O'Fallon J.R., Iturria N., Sebo T., Schaefer P.L., et al. Prognostic significance of apoptotic index and apoptosis/proliferation ratio for patients with high grade astrocytomas. Neurooncology 4 (2002) 179-186
7. Korshunov A., Golanov A., Sycheva R., and Pronin I. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J. Clin. Pathol. 52 (1999) 574-580
8. Haslam R.H., Lambom K.R., Becker L.E., and Israel M.A. Tumour cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma. J. Pediatr. Hematol. Oncol. 20 (1998) 520-527
9. Schiffer D., Dutto A., Cavalla P., Chio A., Migheli A., and Piva R. Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem. Int. 31 (1997) 245-250
10. Kawauchi S., Fukuda T., Oda Y., Saito T., Oga A., Takeshita M., et al. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity and expression of apoptosis-related proteins. Mol. Pathol. 13 (2000) 755-765
11. Xie X., De Angelis P., Clausen O.P., and Boysen M. Prognostic significance of proliferative and apoptosis markers in oral tongue squamous cell carcinomas. Oral Oncol. 35 (1999) 502-509
12. Kaufmann S.H., and Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256 (2000) 42-49
13. Desoize B. Anticancer drug resistance and inhibition of apoptosis. Anticancer Res. 14 (1994) 2291-2294
14. Wu Y.L., Mehew J.W., Heckman C.A., Arcianas M., and Boxer L.M. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20 (2001) 240-251
15. Schiffer D., Cavalla P., Migheli, et al. Apoptosis and cell proliferation in human neuroepithelial tumours. Neurosci. Lett. 195 (1995) 81-84
16. Heesters M.A., Koudstaal J., Go K.G., and Molenaar W.M. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J. Neuro-oncol. 44 (1999) 255-266
17. Haapasalo H., Sallinen S., Sallinen P., Helen P., Jaaskelainen J., Salmi T.T., et al. Clincopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas. Neropathol. Appl. Neurobiol. 25 (1999) 134-142
18. Nakamura M., Konishi N., Tsunoda S., Hiasa Y., Tsuzuki T., Inui T., et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 80 (1997) 242-249
19. Nakamizo A., Inamura T., Ikezaki K., et al. Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumours. J. Neuro-oncol. 57 (2002) 105-114
20. Yew D.T., Wang H.H., and Zheng D.R. Apoptosis in astrocytomas with different grade of malignancy. Acta Neurochir. (Wien) 140 (1998) 341-347
21. Cain K., and Freathy C. Liver toxicity and apoptosis: role of TGF-β1, cytochrome c and the apoptosome. Toxicol. Lett. 120 (2001) 307-315
22. Held-Feindt J., Lutjohann B., Ungefroren H., Mehdron H.M., and Mentlein R. Interaction of transforming growth factor (TGF-β) and epidermal growth factor (EGF) in human glioma cells. Neurooncology 63 (2003) 117-127
23. Golestaneh N., and Mishra B. TGF-β, neuronal stem cells and glioblastoma. Oncogene 24 (2005) 5722-5730
24. Weller M., Constam D.B., Malipiero U., and Fontana A. Transforming growth factor beta 2 induces apoptosis of murine T cell clones without down regulation Bcl-2 mRNA expression. Eur. J. Immunol. 24 (1997) 1293-1300
25. Chattopadhyay N., T-Felt Hansen J., Godbole M.M., and Brown E.M. Transforming growth factor beta receptor family ligands inhibit hepatocyte growth factor synthesis and secretion from astrocytoma cells. Brain Res. Mol. Brain Res. 121 (2004) 146-150
26. Nagashima G., Suzuki R., Asai J.I., Noda M., Fujimoto M., and Fujimoto T. Tissue reconstruction process in the area of peri-tumoural oedema caused by glioblastoma-Immunohistochemical and graphical analysis using brain obtained at autopsy. Acta Neurochir., Suppl. 86 (2003) 507-511
27. Mabrouk G.M., Helal S.A.A., El-Lamie K.I., and Khalifa A. Quantitative measurement of c-erbB-2 p185 and mutant p53 expression in ovarian neoplasms by enzymatic immunoassay. Clin. Chem. 42 (1996) 981-982
28. Bradford N.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72 (1976) 248-254
29. Hawkes R. The dot immunobinding assay. Methods Enzymol. 121 (1986) 484-491
30. Davis F.G., McCarthy B.J., Freels S., Kupelian V., and Bondy M.L. The conditional properties of survival of patients with primary malignant brain tumours: Surveillance, Epidemiology, and End Result (SEER) data. Cancer 85 (1999) 485-491
31. DeAngelis L.M. Brain tumours. N. Engl. Med. 344 (2001) 114-123
32. Ribeiro M.C., Coutinho L.M.B., and Hilbi A. The role of apoptosis, cell proliferation index, BCL-2 and P53 in glioblastoma prognosis. Arq. Neuro-Psiquiatr. 62 (2004) 262-270
33. Kajiwara Y., Yamasaki F., Mama S., Yahara K., Yoshioka H., Sugiyama K., Arita K., and Kurisu K. Expression of survivin in astrocytic tumours: correlation with malignant grade and prognosis. Cancer 97 (2003) 1077-1083
34. Conti A., Ageunnouz M., La Torre D., Cardali S., Angileri F.F., Buemi C., et al. Expression of the tumour necrosis factor receptor-associated factor 1 and 2 and regulation of the nuclear factor-kappa B antiapoptotic activity in human gliomas. J. Neurosurg. 103 (2005) 873-881
35. Watanabe K., Tachibana O., Stata K., Yonekawa Y., Kleihues P., and Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evaluation of primary and secondary glioblastomas. Brain Pathol. 6 (1996) 217-223
36. Fujisawa H., Reis R.M., Nakamura M., Colella S., Yonekawa Y., et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastoma. Lab. Invest. 80 (2000) 65-72
37. Tohma Y., Gratas C., Biernat W., Peraud A., Fukuda M., Yonekawa Y., et al. PTEN (MMACI) mutations are frequent in primary glioblastomas. J. Neuropathol. Exp. Neurol. 57 (1998) 684-689
38. Karcher S., Steiner H.H., Ahmadi R., Zoubaa S., Vasvari G., Bauer H., Unterberg A., and Herold-Mende C. Different angiogenic phenotypes in primary and secondary glioblastomas. Int. J. Cancer 118 (2006) 2182-2189
39. Tso C.L., Freije W.A., Day A., Chen Z., Merriman B., Perlina A., et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 66 (2006) 159-167
40. Sterge R.J., Godt C., Stark A.M., Hugo H.H., and Mehdron H.M. Protein expression of Fas, Fas ligand, Bcl-2 and TGF β-2 and correlation with survival in initial and recurrent human gliomas. J. Neuro-oncol. 67 (2004) 29-39
41. Hulshof M.C., Sminia P., Barten-Van RiJbroek A.D., and Gonzalez D. Prognostic value of TGF-beta in patients with glioblastoma multiforme. Oncol. Rep. 8 (2001) 1107-1110
42. Toth A., Sebestyen A., Barana G., Nagy K., Gondor A., Bocsi J., et al. TGF beta 1 induces caspase-dependent but death receptor independent apoptosis in lymphoid cells. Anticancer Res. 2 (A) (2001) 1207-1212